4 results
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
To assess the percentage of COPD and asthma patients correctly (all critical items correct) using the Accuhaler/Diskus vs Elpenhaler inhaler devices after reading the package insert. Also satisfaction with and preference for an inhaler will be…
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…
this research answers the need to evaluate whether the 780G hybrid closed-loop system in pregnant women with T1DM can improve glycaemic control with less hypoglycaemia. This in turn, might improve pregnancy outcomes in women with T1DM.